
LineaRx Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
Pivot to U.S.-based Supply Chain for Critical Input Materials Completed STONY BROOK, N.Y. April 21, 2025 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company’s majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its […]